Increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the AT1 receptor antagonist telmisartan

IntroductionTreatment of rodents with the AT1 blocker (ARB) telmisartan (TEL) has an anti-adipose effect. Among other mechanisms, we also have attributed the anti-adipose action to diet-independent alterations in gut microbiota. Thus, we aimed here to confirm this mechanism by using the fecal microb...

Full description

Saved in:
Bibliographic Details
Main Authors: Marco L. Freschi, Axel Künstner, Gianna Huber, Ines Stölting, Hauke Busch, Misa Hirose, Walter Raasch
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1453989/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846164580927012864
author Marco L. Freschi
Axel Künstner
Gianna Huber
Gianna Huber
Gianna Huber
Ines Stölting
Hauke Busch
Misa Hirose
Walter Raasch
Walter Raasch
Walter Raasch
author_facet Marco L. Freschi
Axel Künstner
Gianna Huber
Gianna Huber
Gianna Huber
Ines Stölting
Hauke Busch
Misa Hirose
Walter Raasch
Walter Raasch
Walter Raasch
author_sort Marco L. Freschi
collection DOAJ
description IntroductionTreatment of rodents with the AT1 blocker (ARB) telmisartan (TEL) has an anti-adipose effect. Among other mechanisms, we also have attributed the anti-adipose action to diet-independent alterations in gut microbiota. Thus, we aimed here to confirm this mechanism by using the fecal microbiota transfer (FMT) approach.MethodsSeven weeks after initiating a high-fat diet (HFD), C57BL/6N mice received fecal microbiota for 8 weeks from donor mice by oral gavage, continuing HFD feeding. Stool samples came from mice that were treated with TEL (8 mg/kg/d by gavage, 12 weeks), thus remaining lean despite HFD feeding (BL/6>fTEL), while controls received feces samples from vehicle/HFD-treated obese mice (BL/6>fVEH). Microbiota of the stool samples from these acceptor mice was analyzed by 16S rRNA gene amplicon sequencing.ResultsWeight gain was lower in BL6>fTEL than in BL6>fVEH mice after 3 but not 8 weeks. Energy homeostasis, insulin sensitivity, and body composition did not differ between the two groups. β-diversity indicated group differences (F = 2.27, p = 0.005). Although the Firmicutes/Bacteroides ratio did not differ, abundances of distinct phyla, families, and genera varied. Among others, Ruminococcaceae and Desulfovibrionaceae, Desulfovibrionia uncl., and Lachnospiraceae uncl. were lower in BL/6>fTEL than in BL/6>fVEH mice. Moreover, the correlation between body weight and Lachnospiraceae, Desulfovibrionaceae, Desulfovibrionia uncl., or Desulfovibrio was positive in BL/6>fVEH and negative in BL/6>fTEL mice.DiscussionAs FMT from TEL-pretreated mice influences the microbiota in acceptor mice with slight weight-reducing effects, we confirm the relevance of TEL-related microbiota changes for weight reduction, most likely independent of the transferred stool-residual TEL effect on the host metabolism.
format Article
id doaj-art-e96eb19e48e7441fa6f4a6893a4644ac
institution Kabale University
issn 1663-9812
language English
publishDate 2024-11-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj-art-e96eb19e48e7441fa6f4a6893a4644ac2024-11-18T04:23:13ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-11-011510.3389/fphar.2024.14539891453989Increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the AT1 receptor antagonist telmisartanMarco L. Freschi0Axel Künstner1Gianna Huber2Gianna Huber3Gianna Huber4Ines Stölting5Hauke Busch6Misa Hirose7Walter Raasch8Walter Raasch9Walter Raasch10Institute of Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Lübeck, GermanyMedical Systems Biology Group, Institute of Experimental Dermatology, University of Lübeck, Lübeck, GermanyInstitute of Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Lübeck, GermanyDZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Lübeck, GermanyCBBM (Center of Brain, Behavior and Metabolism), Lübeck, GermanyInstitute of Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Lübeck, GermanyMedical Systems Biology Group, Institute of Experimental Dermatology, University of Lübeck, Lübeck, GermanyInstitute of Experimental Dermatology, University of Lübeck, Lübeck, GermanyInstitute of Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Lübeck, GermanyDZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Lübeck, GermanyCBBM (Center of Brain, Behavior and Metabolism), Lübeck, GermanyIntroductionTreatment of rodents with the AT1 blocker (ARB) telmisartan (TEL) has an anti-adipose effect. Among other mechanisms, we also have attributed the anti-adipose action to diet-independent alterations in gut microbiota. Thus, we aimed here to confirm this mechanism by using the fecal microbiota transfer (FMT) approach.MethodsSeven weeks after initiating a high-fat diet (HFD), C57BL/6N mice received fecal microbiota for 8 weeks from donor mice by oral gavage, continuing HFD feeding. Stool samples came from mice that were treated with TEL (8 mg/kg/d by gavage, 12 weeks), thus remaining lean despite HFD feeding (BL/6>fTEL), while controls received feces samples from vehicle/HFD-treated obese mice (BL/6>fVEH). Microbiota of the stool samples from these acceptor mice was analyzed by 16S rRNA gene amplicon sequencing.ResultsWeight gain was lower in BL6>fTEL than in BL6>fVEH mice after 3 but not 8 weeks. Energy homeostasis, insulin sensitivity, and body composition did not differ between the two groups. β-diversity indicated group differences (F = 2.27, p = 0.005). Although the Firmicutes/Bacteroides ratio did not differ, abundances of distinct phyla, families, and genera varied. Among others, Ruminococcaceae and Desulfovibrionaceae, Desulfovibrionia uncl., and Lachnospiraceae uncl. were lower in BL/6>fTEL than in BL/6>fVEH mice. Moreover, the correlation between body weight and Lachnospiraceae, Desulfovibrionaceae, Desulfovibrionia uncl., or Desulfovibrio was positive in BL/6>fVEH and negative in BL/6>fTEL mice.DiscussionAs FMT from TEL-pretreated mice influences the microbiota in acceptor mice with slight weight-reducing effects, we confirm the relevance of TEL-related microbiota changes for weight reduction, most likely independent of the transferred stool-residual TEL effect on the host metabolism.https://www.frontiersin.org/articles/10.3389/fphar.2024.1453989/fullobesityrenin-angiotensin aldosterone system (RAAS)telmisartanmicrobiota transferdesulovibrioweight reduction
spellingShingle Marco L. Freschi
Axel Künstner
Gianna Huber
Gianna Huber
Gianna Huber
Ines Stölting
Hauke Busch
Misa Hirose
Walter Raasch
Walter Raasch
Walter Raasch
Increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the AT1 receptor antagonist telmisartan
Frontiers in Pharmacology
obesity
renin-angiotensin aldosterone system (RAAS)
telmisartan
microbiota transfer
desulovibrio
weight reduction
title Increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the AT1 receptor antagonist telmisartan
title_full Increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the AT1 receptor antagonist telmisartan
title_fullStr Increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the AT1 receptor antagonist telmisartan
title_full_unstemmed Increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the AT1 receptor antagonist telmisartan
title_short Increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the AT1 receptor antagonist telmisartan
title_sort increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the at1 receptor antagonist telmisartan
topic obesity
renin-angiotensin aldosterone system (RAAS)
telmisartan
microbiota transfer
desulovibrio
weight reduction
url https://www.frontiersin.org/articles/10.3389/fphar.2024.1453989/full
work_keys_str_mv AT marcolfreschi increaseinbodyweightisloweredwhenmicereceivedfecalmicrobiotatransferfromdonormicetreatedwiththeat1receptorantagonisttelmisartan
AT axelkunstner increaseinbodyweightisloweredwhenmicereceivedfecalmicrobiotatransferfromdonormicetreatedwiththeat1receptorantagonisttelmisartan
AT giannahuber increaseinbodyweightisloweredwhenmicereceivedfecalmicrobiotatransferfromdonormicetreatedwiththeat1receptorantagonisttelmisartan
AT giannahuber increaseinbodyweightisloweredwhenmicereceivedfecalmicrobiotatransferfromdonormicetreatedwiththeat1receptorantagonisttelmisartan
AT giannahuber increaseinbodyweightisloweredwhenmicereceivedfecalmicrobiotatransferfromdonormicetreatedwiththeat1receptorantagonisttelmisartan
AT inesstolting increaseinbodyweightisloweredwhenmicereceivedfecalmicrobiotatransferfromdonormicetreatedwiththeat1receptorantagonisttelmisartan
AT haukebusch increaseinbodyweightisloweredwhenmicereceivedfecalmicrobiotatransferfromdonormicetreatedwiththeat1receptorantagonisttelmisartan
AT misahirose increaseinbodyweightisloweredwhenmicereceivedfecalmicrobiotatransferfromdonormicetreatedwiththeat1receptorantagonisttelmisartan
AT walterraasch increaseinbodyweightisloweredwhenmicereceivedfecalmicrobiotatransferfromdonormicetreatedwiththeat1receptorantagonisttelmisartan
AT walterraasch increaseinbodyweightisloweredwhenmicereceivedfecalmicrobiotatransferfromdonormicetreatedwiththeat1receptorantagonisttelmisartan
AT walterraasch increaseinbodyweightisloweredwhenmicereceivedfecalmicrobiotatransferfromdonormicetreatedwiththeat1receptorantagonisttelmisartan